---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-323704"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2025-12-18T23:59:59+00:00"
generated_at: "2026-05-16T12:46:03.637762+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology MICVO Phase 1 shows 46% ORR monotherapy, 71% ORR with Keytruda in HNSCC

## Summary
- MICVO monotherapy at 5.4 mg/kg: 46% confirmed ORR (6/13), 92% DCR in 2L+ R/M HNSCC; no Grade 4/5 TRAEs.
- MICVO + Keytruda (3.6/4.4 mg/kg): 71% confirmed ORR (5/7), 100% DCR in 1L/2L+ HNSCC; no TRAE discontinuations.
- Sold Enzeshu royalty rights for $11M one-time cash; cash runway extends into Q4 2026.
- Monotherapy update expected mid-2026; combo update in 2H26; FDA alignment on pivotal study design obtained.

## SEC filing metadata
- accession: 0001193125-25-323704
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2025-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000119312525323704/0001193125-25-323704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000119312525323704/pyxs-20251218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-323704
- JSON: https://secwatch.observer/filing/0001193125-25-323704.json
- Plain text: https://secwatch.observer/filing/0001193125-25-323704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.